Vir Biotechnology (VIR) Projected to Post Quarterly Earnings on Wednesday

Vir Biotechnology (NASDAQ:VIR) is projected to issue its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect the company to announce earnings of ($0.01) per share and revenue of $55.4890 million for the quarter. Parties can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 4:30 PM ET.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings data on Monday, February 23rd. The company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.11. The firm had revenue of $64.07 million during the quarter, compared to the consensus estimate of $19.91 million. Vir Biotechnology had a negative return on equity of 49.31% and a negative net margin of 638.88%.The business’s revenue for the quarter was up 417.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.76) EPS. On average, analysts expect Vir Biotechnology to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Vir Biotechnology Price Performance

Shares of NASDAQ:VIR opened at $10.00 on Monday. The company has a market capitalization of $1.61 billion, a PE ratio of -3.16 and a beta of 1.70. The business has a fifty day moving average price of $9.51 and a two-hundred day moving average price of $7.47. Vir Biotechnology has a 1 year low of $4.16 and a 1 year high of $11.66.

Analysts Set New Price Targets

VIR has been the subject of a number of recent analyst reports. Morgan Stanley upped their price objective on Vir Biotechnology from $20.00 to $24.00 and gave the company an “overweight” rating in a research note on Tuesday, February 24th. HC Wainwright upped their price objective on Vir Biotechnology from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Needham & Company LLC upped their price objective on Vir Biotechnology from $14.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, February 24th. Wall Street Zen upgraded Vir Biotechnology from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Finally, Raymond James Financial raised Vir Biotechnology from an “outperform” rating to a “strong-buy” rating and set a $19.00 price target on the stock in a research report on Tuesday, February 24th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $20.38.

Insider Transactions at Vir Biotechnology

In other news, CEO Backer Marianne De sold 72,559 shares of the company’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $9.16, for a total transaction of $664,640.44. Following the transaction, the chief executive officer owned 948,145 shares of the company’s stock, valued at $8,685,008.20. This represents a 7.11% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Brent Sabatini sold 7,711 shares of the company’s stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $9.12, for a total value of $70,324.32. Following the transaction, the chief accounting officer directly owned 61,902 shares in the company, valued at $564,546.24. This represents a 11.08% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 235,816 shares of company stock worth $2,156,598 over the last quarter. 16.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Vir Biotechnology

A number of institutional investors have recently added to or reduced their stakes in VIR. AQR Capital Management LLC lifted its holdings in Vir Biotechnology by 2,088.4% during the 1st quarter. AQR Capital Management LLC now owns 268,297 shares of the company’s stock worth $1,739,000 after purchasing an additional 256,037 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in Vir Biotechnology during the 1st quarter worth about $359,000. Goldman Sachs Group Inc. lifted its holdings in Vir Biotechnology by 43.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 742,674 shares of the company’s stock worth $4,813,000 after purchasing an additional 225,544 shares in the last quarter. Woodline Partners LP lifted its holdings in Vir Biotechnology by 245.6% during the 1st quarter. Woodline Partners LP now owns 466,737 shares of the company’s stock worth $3,024,000 after purchasing an additional 331,701 shares in the last quarter. Finally, Focus Partners Wealth lifted its holdings in Vir Biotechnology by 15.3% during the 1st quarter. Focus Partners Wealth now owns 19,317 shares of the company’s stock worth $125,000 after purchasing an additional 2,566 shares in the last quarter. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical?stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell?based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID?19, HIV, hepatitis B, and tuberculosis.